New cancer drug enters first human trials for multiple tumor types
NCT ID NCT06714617
Summary
This is the first human study testing the safety and early effects of an experimental drug called BL-M17D1 in people with advanced cancers that have a specific marker called HER2. The trial will enroll 120 adults with various hard-to-treat cancers, including breast, lung, and stomach cancers, who have already tried standard treatments. The main goal is to find a safe dose and understand how the body handles the drug, which is given as an infusion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hematology Oncology Associates of the Treasure Cost
Port Saint Lucie, Florida, 34952, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
SCRI-Denver HealthOne
Denver, Colorado, 37203, United States
-
SCRI-Florida Cancer Center Specialists Lake Mary
Lake Mary, Florida, 32746, United States
-
SCRI-Florida Cancer Center Specialists Sarasota
Sarasota, Florida, 34236, United States
-
SCRI-Oncology Partners
Nashville, Tennessee, 37203, United States
-
SCRI-Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, 19107, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.